Sign In
Buy ABCL
$5.80
-0.665 (-10.29%)
At Close: Jul 20, 2026
AI Meets Biotech: 3 Top Stocks Transforming Medical Science
01:00pm, Saturday, 16'th Dec 2023
One of the biggest stories of the year has been the rise of AI in every industry. This trend will hit biotech stocks no less than any others.
Buy AbCellera Biologics's Revolutionizing AI-Powered Drug Development Platform
11:39pm, Thursday, 07'th Dec 2023
AbCellera Biologics is a biotech company using AI-powered platforms to discover and analyze target-specific antibodies. The company emphasizes partnerships to expedite drug development and has two dru
AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023
04:05pm, Thursday, 16'th Nov 2023
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023.
AbCellera Biologics Inc. (ABCL) Q3 2023 Earnings Call Transcript
09:18pm, Thursday, 02'nd Nov 2023
AbCellera Biologics Inc. (NASDAQ:ABCL ) Q3 2023 Results Conference Call November 2, 2023 5:00 PM ET Company Participants Tryn Stimart - Chief Legal & Compliance Officer Carl Hansen - President, CEO An
New Strong Buy Stocks for October 26th
07:31am, Thursday, 26'th Oct 2023
GRPN, NRIX, RNLX, ABCL and SMAR have been added to the Zacks Rank #1 (Strong Buy) List on October 26, 2023.
AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023
04:05pm, Wednesday, 11'th Oct 2023
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023.
3 AI Stocks You'll Regret Not Buying Soon
03:06pm, Tuesday, 08'th Aug 2023
Artificial intelligence ( AI ) will have a profound impact on the medical industry, where it could help accelerate drug discovery and patient treatment, creating big opportunities for these top AI sto
AbCellera Biologics Inc. (ABCL) Q2 2023 Earnings Call Transcript
11:03pm, Thursday, 03'rd Aug 2023
AbCellera Biologics Inc. (NASDAQ:ABCL ) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Company Participants Tryn Stimart - Chief Legal & Compliance Officer Carl Hansen - Chief Executive Of
Does AbCellera Biologics Inc. (ABCL) Have the Potential to Rally 242.09% as Wall Street Analysts Expect?
11:39am, Tuesday, 25'th Jul 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 242.1% in AbCellera Biologics Inc. (ABCL). While the effectiveness of this highly sought-after metric is questi
Looking for Biotech AI Stocks? 3 Names That Will Benefit From the AI Boom
08:43pm, Saturday, 08'th Jul 2023
AI is coming to biotech in a big way. From protein folding to drug screening, from studying cells to studying populations, the AI boom has long been an asset to biological research and drug discovery.
AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023
04:05pm, Monday, 29'th May 2023
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023.
7 Growth Stocks That Could Double Your Money in 2023
02:57pm, Sunday, 14'th May 2023
While the recent slow activity in the major indices clouds the narrative, you can still enjoy opportunities for growth stocks that could double your money. To be sure, you must be willing to accept so
AbCellera Biologics: TCE Program Alone Could Be Worth More Than The Current Market Cap
12:42am, Saturday, 06'th May 2023
AbCellera reported results from the first quarter on May 4th. To put it bluntly, the actual earnings print means next to nothing in this name at this stage. The company had a very busy and productive
AbCellera Biologics Inc. (ABCL) Q1 2023 Earnings Call Transcript
09:30pm, Thursday, 04'th May 2023
AbCellera Biologics Inc. (NASDAQ:ABCL ) Q1 2023 Results Conference Call May 4, 2023 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Dr. Carl Hansen - Chairman, Chief
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Tops Revenue Estimates
07:01pm, Thursday, 04'th May 2023
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to earnings of $0.54 per share a year ago.
